Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

USP11 Promotes Prostate Cancer Progression by Up-Regulating AR and C-myc Activity

July 26, 2024

[Proceedings of The National Academy of Sciences of The United States of America] Investigators found that the deubiquitinase USP11 targeted both androgen receptor and c-Myc in prostate cancer (PCa). USP11 expression was up-regulated in metastatic PCa and castration-resistant prostate cancer.

Effects of Protein Restriction on Insulin-Like Growth Factor (IGF)-1 in Men with Prostate Cancer: Results from a Randomized Clinical Trial

July 26, 2024

[Biomarker Research] Researchers demonstrated that protein restriction without calorie restriction did not reduce serum IGF-1 concentration or increase IGFBP-1 and IGFBP-3 in men with localized prostate cancer.

Notch Signaling Suppresses Neuroendocrine Differentiation and Alters the Immune Microenvironment in Advanced Prostate Cancer

July 26, 2024

[Journal of Clinical Investigation] While Notch could be oncogenic in early prostate cancer, scientists identified significant downregulation of the Notch pathway during prostate cancer progression from adenocarcinoma to neuroendocrine prostate cancer where it functioned as a tumor suppressor.

Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial

July 26, 2024

[Journal of Clinical Oncology] Researchers determined if Stockholm3 could improve prostate cancer detection in a diverse cohort. An observational prospective multicentered clinical trial, supplemented by prospectively recruited participants in a urology clinic setting included men with suspicion of prostate cancer and underwent prostate biopsy.

Epitranscriptomic Mechanisms of Androgen Signalling and Prostate Cancer

July 26, 2024

[Neoplasia] Given the need for novel approaches to treat PCa (prostate cancer), there is significant interest in new therapies that target m6A that modulate androgen receptor expression and androgen signaling. This review critically summarizes the potential benefit of such epitranscriptomic therapies for PCa patients.

Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer

July 26, 2024

[Blue Earth Therapeutics] Blue Earth Therapeutics announced the signing of a clinical research collaboration with University College London (UCL). The collaboration is centered on a Phase I/II trial designed to evaluate the safety, tolerability, radiation dosimetry, and anti-tumor activity of the company’s 225Ac-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer who have previously responded to lutetium 177 (177Lu)-PSMA therapy.

Clinical Implications of Wnt Pathway Genetic Alterations in Men with Advanced Prostate Cancer

July 19, 2024

[Prostate Cancer and Prostatic Diseases] Investigators utilized the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort clinical-genomic database for this retrospective analysis.

Targeting Valine Catabolism to Inhibit Metabolic Reprogramming in Prostate Cancer

July 19, 2024

[Cell Death & Disease] Through the suppression of branched-chain amino acid (BCAA) availability, researchers reported significantly reduced lipid content, strongly indicating that BCAAs were important lipogenic fuels in prostate cancer.

Embryonic Microenvironment Suppresses YY1 and YY1-Related Genes in Prostate Cancer Stem Cells

July 19, 2024

[Pathology - Research and Practice] To investigate the embryonic microenvironment impact on Yin yang 1 (YY1) expression in CSC populations, firstly cancer stem cells (CSCs) were microinjected into the inner cell mass of blastocysts and then prostate CSCs were co-cultured with blastocysts.

A Novel Prognostic Model of De Novo Metastatic Hormone-Sensitive Prostate Cancer to Optimize Treatment Intensity

July 19, 2024

[International Journal of Clinical Oncology] 1092 Japanese patients diagnosed with de novo metastatic hormone-sensitive prostate cancer between 2014 and 2020 were registered. The patients treated with androgen deprivation therapy and first-generation anti-androgens were assigned to the discovery or validation cohorts.

The PP2A Regulator IER5L Supports Prostate Cancer Progression

July 19, 2024

[Cell Death & Disease] The authors showed that the less studied member of the Immediate Early Response (IER) family, IER 5 like (IER5L), was upregulated in aggressive prostate cancer.

Dr. Tanya Stoyanova Receives $1.8 Million to Reveal New Treatment Strategies for Advanced Prostate Cancer

July 19, 2024

[UCLA Health] Dr. Tanya Stoyanova was awarded a $1.8 million grant from the National Cancer Institute to identify new drivers and test new therapeutic strategies for advanced treatment-resistant prostate cancer.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.